COMP <GO>
EMN vs FCX // EV/EBITDA & P/E VALUATION
Eastman Chemical Company (NYSE) VS. Freeport-McMoRan Inc. (NYSE) • 15-METRIC TALLY: EMN 6
— FCX 8
▲ EV/EBITDA & P/E VALUATION LEADER: EMN
LAST: $65.34 (-2.16%) • MKT CAP: $7.64B
valuation
10.9x
LAST: $61.77 (-1.91%) • MKT CAP: $90.43B
valuation
13.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EMN VS. FCX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EMN | FCX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 21.10% | 26.10% | -5.00 | FCX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.80% | 21.50% | -16.70 | FCX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 10.9x | 13.4x | -2.50 | EMN | /valuation <GO> |
| Free Cash Flow Yield | 5.46% | 4.71% | +0.75 | EMN | /fcf-yield <GO> |
| Operating Margin | 6.60% | 25.90% | -19.30 | FCX | /operating-margins <GO> |
| Net Profit Margin | 5.40% | 8.80% | -3.40 | FCX | /net-margins <GO> |
| Revenue Growth (YoY) | -6.70% | 0.10% | -6.80 | FCX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 4.90% | 0.91% | +3.99 | EMN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.28 | 3.08 | -0.80 | FCX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | FCX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.2 | 37.3 | +16.90 | EMN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 0.95 | +0.11 | EMN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 15.3x | 40.1x | -24.80 | EMN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.64B | $90.43B | -$82.79B | FCX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EMN REV | FCX REV | EMN GROSS % | FCX GROSS % | EMN FCF | FCX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.75B | $25.19B | 21.1% | 26.1% | $424.0M | $4.48B |
| FY 2024 | $9.38B | $25.17B | 24.4% | 29.3% | $688.0M | $6.03B |
| FY 2023 | $9.21B | $22.70B | — | — | $959.5M | $4.26B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EMN // BETA 1.06
FCX // BETA 0.95